Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands.
Int J Cardiol. 2013 Oct 9;168(4):3212-6. doi: 10.1016/j.ijcard.2013.04.114. Epub 2013 May 3.
This study aims to investigate indications and complications of permanent cardiac pacing in adults with congenital heart disease (CHD).
Two-hundred and seventy-four CHD patients were identified who underwent permanent pacemaker implantation between 1972 and 2009. The indication for pacing was acquired sinus node or AV node conduction disease (63%), sinus node or AV node conduction disease after cardiac surgery (28%), and drug/arrhythmia-related indications (9%). Patients with complex CHD received a pacemaker at younger age (23 versus 31 years, p<0.0001) and more often received an epicardial pacing system (51% versus 23%, p<0.0001) compared to those with simple or moderate CHD. Twenty-nine patients (10.6%) had a periprocedural complication during the primary pacemaker implantation (general population: 5.2%). The most common acute complications were lead dysfunction (4.0%), bleeding (2.6%), pocket infection (1.5%) and pneumothorax (1.5%). During a median follow-up of 12 years, pacemaker-related complications requiring intervention occurred in 95 patients (34.6%). The most common late pacemaker-related complications included lead failure (24.8%), pacemaker dysfunction/early battery depletion (5.1%), pacemaker migration (4.7%) and erosion (4.7%). Pacemaker implantation at younger age (<18 years) was an independent predictor of late pacemaker-related complication (adjusted hazard ratio 1.68, 95% confidence interval 1.07 to 2.63, p=0.023).
The risk of periprocedural complications seems higher in the CHD population compared to the general population and more than one-third of CHD patients encountered a pacemaker-related complication during long-term follow-up. This risk increases for those who receive a pacemaker at younger age.
本研究旨在探讨先天性心脏病(CHD)成人患者行永久性心脏起搏的适应证和并发症。
共纳入 274 例 1972 年至 2009 年期间行永久性起搏器植入的 CHD 患者。起搏的适应证为窦房结或房室结传导疾病(63%)、心脏手术后的窦房结或房室结传导疾病(28%)和药物/心律失常相关适应证(9%)。与简单或中度 CHD 患者相比,复杂 CHD 患者接受起搏器的年龄更小(23 岁比 31 岁,p<0.0001),更常接受心外膜起搏系统(51%比 23%,p<0.0001)。29 例(10.6%)患者在初次起搏器植入过程中发生围手术期并发症(普通人群:5.2%)。最常见的急性并发症是导线功能障碍(4.0%)、出血(2.6%)、囊袋感染(1.5%)和气胸(1.5%)。中位随访 12 年期间,95 例(34.6%)患者发生需要干预的起搏器相关并发症。最常见的晚期起搏器相关并发症包括导线故障(24.8%)、起搏器功能障碍/早期电池耗竭(5.1%)、起搏器移位(4.7%)和侵蚀(4.7%)。年龄<18 岁时行起搏器植入是晚期起搏器相关并发症的独立预测因素(校正风险比 1.68,95%置信区间 1.07 至 2.63,p=0.023)。
与普通人群相比,CHD 人群围手术期并发症的风险似乎更高,超过三分之一的 CHD 患者在长期随访期间发生与起搏器相关的并发症。对于年龄较小接受起搏器治疗的患者,这种风险会增加。